![Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma – Ronny Allan – Living with Neuroendocrine Cancer Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma – Ronny Allan – Living with Neuroendocrine Cancer](https://i0.wp.com/ronnyallan.net/wp-content/uploads/2022/06/Dostarlimab-clinical-trial.jpg?fit=1200%2C675&ssl=1)
Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma – Ronny Allan – Living with Neuroendocrine Cancer
![Pharmaceuticals | Free Full-Text | Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update | HTML Pharmaceuticals | Free Full-Text | Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-14-00717/article_deploy/html/images/pharmaceuticals-14-00717-g004.png)
Pharmaceuticals | Free Full-Text | Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update | HTML
![ScienceofParkinsons on Twitter: "Interesting analysis & discussion on clinical trial matters like enrollment, sponsors, trials sites, biomarkers, & geography. Plus what the category definition "disease modifying" actually means in #Parkinsons https://t ... ScienceofParkinsons on Twitter: "Interesting analysis & discussion on clinical trial matters like enrollment, sponsors, trials sites, biomarkers, & geography. Plus what the category definition "disease modifying" actually means in #Parkinsons https://t ...](https://pbs.twimg.com/media/EeR2_9HXoAAtewP.jpg)
ScienceofParkinsons on Twitter: "Interesting analysis & discussion on clinical trial matters like enrollment, sponsors, trials sites, biomarkers, & geography. Plus what the category definition "disease modifying" actually means in #Parkinsons https://t ...
![Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/778f7097-36c5-4170-96b9-368fddc775e4/gr1.jpg)
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
![The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials | Journal of Hematology & Oncology | Full Text The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-022-01227-1/MediaObjects/13045_2022_1227_Fig1_HTML.png)
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials | Journal of Hematology & Oncology | Full Text
![ScienceofParkinsons on Twitter: "The study explores data from 145 #Parkinsons clinical trials that were ongoing during 2019-2020, breaking them down into phase & agent type to give the PD community a broad ScienceofParkinsons on Twitter: "The study explores data from 145 #Parkinsons clinical trials that were ongoing during 2019-2020, breaking them down into phase & agent type to give the PD community a broad](https://pbs.twimg.com/media/EeR1WzDXsAYuL0c.jpg)
ScienceofParkinsons on Twitter: "The study explores data from 145 #Parkinsons clinical trials that were ongoing during 2019-2020, breaking them down into phase & agent type to give the PD community a broad
![Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | SpringerLink Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-020-00120-3/MediaObjects/43440_2020_120_Fig1_HTML.png)
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies | SpringerLink
![China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData - GlobalData China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData - GlobalData](https://www.globaldata.com/wp-content/uploads/2020/11/PR11472a-1024x549.png)
China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData - GlobalData
![PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials - Journal of Thoracic Oncology PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/da9f2367-a3b0-47b6-bd19-8bbfaa25dce2/fx1_lrg.jpg)
PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials - Journal of Thoracic Oncology
![The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease](https://www.iospress.nl/wp-content/uploads/2020/08/JPD10-3_PR3_image.jpg)
The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease
![Frontiers | Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020) Frontiers | Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)](https://www.frontiersin.org/files/Articles/777698/fmed-08-777698-HTML/image_m/fmed-08-777698-g001.jpg)